• Vaccine Name: Adacel
• Target Pathogen: Clostridium tetani
• Target Disease: Tetanus
• Product Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
• Tradename: Adacel
• Manufacturer: Sanofi Pasteur, Ltd (USA: License #1726)
• Vaccine Ontology ID: VO_0000005
• CDC CVX code: 20, 115
• Type: Toxoid vaccine
• Status: Licensed
• Location Licensed: USA: License #1726
• Host Species for Licensed Use: Human
• Antigen: Pertussis
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000128
  • Description: It is a sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components adsorbed onto aluminum phosphate, for intramuscular administration.(FDA: Adacel)
• Preparation: Clostridium tetani is grown in modified Mueller-Miller casamino acid medium without beef heart infusion. Tetanus toxin is detoxified with formaldehyde and purified by ammonium sulfate fractionation and diafiltration. Diphtheria and tetanus toxoids are individually adsorbed onto aluminum phosphate.(FDA: Adacel)
• Immunization Route: Intramuscular injection (i.m.)
• Storage: Adacel vaccine should be stored at 2° to 8°C (35° to 46°F). DO NOT FREEZE
• Approved Age for Licensed Use: Adacel vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis as a single dose in persons 11 through 64 years of age.
• Contraindication: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of Adacel vaccine or any other tetanus toxoid, diphtheria toxoid or pertussis containing vaccine or any other component of this vaccine is a contraindication to vaccination with Adacel vaccine. (FDA: Adacel)
• Description: It is a sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components adsorbed onto aluminum phosphate, for intramuscular administration.(FDA: Adacel)

Human Response

• Vaccination Protocol: The use of Adacel vaccine as a primary series, or to complete the primary series, has not been studied. Vaccination with Adacel vaccine may not protect all of vaccinated individuals (FDA: Adacel).
• Immune Response: Strong antibody response was induced after the first immunization. The antibody response after booster immunization was also strong, esp. for young age group. The Adacel-induced immune response levels after the first immunization and booster immunization were comparable to those induced by a US licensed Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (Td) vaccine manufactured by Sanofi Pasteur Inc., Swiftwater, PA (FDA: Adacel).
• Side Effects: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of Adacel vaccine. Also, headache, body ache or muscle weakness, tiredness, chills, sore and swollen joints, nausea, lymph node swelling, diarrhea, vomiting, and rash may result.(FDA: Adacel)